{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:57:03Z","timestamp":1790607423596,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08087-0","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:11:20Z","timestamp":1790604680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-2885","authenticated-orcid":false,"given":"C\u00e6cilie","family":"Ottosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ea","family":"Kragelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Abildgaard","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi Quoc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakina Kousgaard","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene Borup","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Lerche","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie H\u00f8ier","family":"Gamborg-Kvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen-Lise Garm","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sofie","family":"Brems-Eskildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Bach","family":"Callesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"3","key":"8087_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"8087_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"8087_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejca.2022.11.039","volume":"180","author":"AKM Jakobsen","year":"2023","unstructured":"Jakobsen AKM, Spindler KG (2023) ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology. Eur J Cancer 180:180\u2013183. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.039","journal-title":"Eur J Cancer"},{"key":"8087_CR4","doi-asserted-by":"publisher","first-page":"175883592311715","DOI":"10.1177\/17588359231171580","volume":"15","author":"KG Spindler","year":"2023","unstructured":"Spindler KG, Jakobsen A (2023) Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer. Ther Adv Med Oncol 15:17588359231171580. https:\/\/doi.org\/10.1177\/17588359231171580","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"8087_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","volume":"20","author":"A Kustanovich","year":"2019","unstructured":"Kustanovich A, Schwartz R, Peretz T, Grinshpun A (2019) Life and death of circulating cell-free DNA. Cancer Biol Ther 20(8):1057\u20131067. https:\/\/doi.org\/10.1080\/15384047.2019.1598759","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"8087_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-024-00626-6","volume":"10","author":"O Amato","year":"2024","unstructured":"Amato O, Giannopoulou N, Ignatiadis M (2024) Circulating tumor DNA validity and potential uses in metastatic breast cancer. NPJ Breast Cancer 10(1):21. https:\/\/doi.org\/10.1038\/s41523-024-00626-6","journal-title":"NPJ Breast Cancer"},{"issue":"27","key":"8087_CR7","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.22.01063","volume":"40","author":"NL Henry","year":"2022","unstructured":"Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A (2022) Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 40(27):3205\u20133221. https:\/\/doi.org\/10.1200\/JCO.22.01063","journal-title":"J Clin Oncol"},{"issue":"12","key":"8087_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.24.00248","volume":"42","author":"HJ Burstein","year":"2024","unstructured":"Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL, Targeted Therapy in Metastatic Breast Cancer Expert P (2024) Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. J Clin Oncol 42(12):1450\u20131453. https:\/\/doi.org\/10.1200\/JCO.24.00248","journal-title":"J Clin Oncol"},{"issue":"18","key":"8087_CR9","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.23.00638","volume":"41","author":"HJ Burstein","year":"2023","unstructured":"Burstein HJ, DeMichele A, Somerfield MR, Henry NL, Biomarker T, Endocrine (2023) Targeted Therapy in Metastatic Breast Cancer Expert P. Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 41(18):3423\u20133425. https:\/\/doi.org\/10.1200\/JCO.23.00638","journal-title":"J Clin Oncol"},{"issue":"1","key":"8087_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S\u2026 Moher D. (2021) The PRISMA 2020 statement:an updated guideline for reporting systematic reviews. Syst Rev 10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"8087_CR11","unstructured":"Innovation VH (2025) Covidence systematic review software"},{"issue":"6","key":"8087_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","volume":"144","author":"JA Hayden","year":"2006","unstructured":"Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144(6):427\u2013437. https:\/\/doi.org\/10.7326\/0003-4819-144-6-200603210-00010","journal-title":"Ann Intern Med"},{"issue":"7414","key":"8087_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"8087_CR14","unstructured":"Deeks JJ, HJ, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2024) Cochrane handbook for systematic reviews of interventions. Version 6.5. Cochrane"},{"key":"8087_CR15","unstructured":"Team RC (2024) R: a language and environment for statistical computing. In: Computing RFfS"},{"key":"8087_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41523-018-0093-3","volume":"4","author":"S Kumar","year":"2018","unstructured":"Kumar S, Lindsay D, Chen QB, Garrett AL, Tan XM, Anders CK, Carey LA, Gupta GP (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39. https:\/\/doi.org\/10.1038\/s41523-018-0093-3","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"8087_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-17-1038","volume":"18","author":"R Shatsky","year":"2019","unstructured":"Shatsky R, Parker BA, Bui NQ, Helsten T, Schwab RB, Boles SG, Kurzrock R (2019) Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. Mol Cancer Ther 18(5):1001\u20131011. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1038","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"8087_CR18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/ijc.32536","volume":"146","author":"F Ma","year":"2020","unstructured":"Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, Zhu W, Guan X, Li C, Qian H, Xia X, Yang L, Zhang J, Husain H, Liao Z, Futreal A, Huang J, Yi X, Xu B (2020) Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer 146(5):1359\u20131368. https:\/\/doi.org\/10.1002\/ijc.32536","journal-title":"Int J Cancer"},{"issue":"3","key":"8087_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/1878-0261.12617","volume":"14","author":"DT Kruger","year":"2020","unstructured":"Kruger DT, Jansen M, Konings I, Dercksen WM, Jager A, Oulad Hadj J, Sleijfer S, Martens JWM, Boven E (2020) High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane. Mol Oncol 14(3):490\u2013503. https:\/\/doi.org\/10.1002\/1878-0261.12617","journal-title":"Mol Oncol"},{"issue":"3","key":"8087_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/jnci\/djaa087","volume":"113","author":"B O\u2019Leary","year":"2021","unstructured":"O\u2019Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, Andre F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Bartlett CH, Turner NC (2021) Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. J Natl Cancer Inst 113(3):309\u2013317. https:\/\/doi.org\/10.1093\/jnci\/djaa087","journal-title":"J Natl Cancer Inst"},{"key":"8087_CR21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1200\/PO.19.00396","volume":"4","author":"MJ Wongchenko","year":"2020","unstructured":"Wongchenko MJ, Kim SB, Saura C, Oliveira M, Lipson D, Kennedy M, Greene M, Breese V, Mani A, Xu N, Dent R (2020) Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. JCO Precis Oncol 4:1012\u20131024. https:\/\/doi.org\/10.1200\/PO.19.00396","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"8087_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41392-021-00662-9","volume":"6","author":"Z Yi","year":"2021","unstructured":"Yi Z, Ma F, Rong G, Liu B, Guan Y, Li J, Sun X, Wang W, Guan X, Mo H, Wang J, Qian H, Xu B (2021) The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther 6(1):251. https:\/\/doi.org\/10.1038\/s41392-021-00662-9","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"8087_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41523-021-00331-8","volume":"7","author":"A Gombos","year":"2021","unstructured":"Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G (2021) FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ Breast Cancer 7(1):125. https:\/\/doi.org\/10.1038\/s41523-021-00331-8","journal-title":"NPJ Breast Cancer"},{"key":"8087_CR24","doi-asserted-by":"publisher","unstructured":"Page K, Martinson LJ, Fernandez-Garcia D, Hills A, Gleason KLT, Gray MC, Rushton AJ, Nteliopoulos G, Hastings RK, Goddard K, Ions C, Parmar V, Primrose L, Openshaw MR, Guttery DS, Palmieri C, Ali S, Stebbing J, Coombes RC, Shaw JA (2021) Circulating tumor DNA profiling from breast cancer screening through to metastatic disease. JCO Precis Oncol 5. https:\/\/doi.org\/10.1200\/PO.20.00522","DOI":"10.1200\/PO.20.00522"},{"issue":"10","key":"8087_CR25","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/1878-0261.13188","volume":"16","author":"R Sabatier","year":"2022","unstructured":"Sabatier R, Vicier C, Garnier S, Guille A, Carbuccia N, Isambert N, Dalenc F, Robert M, Levy C, Pakradouni J, Adelaide J, Chaffanet M, Sfumato P, Mamessier E, Bertucci F, Goncalves A (2022) Circulating tumor DNA predicts efficacy of a dual AKT\/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB\/II study. Mol Oncol 16(10):2057\u20132070. https:\/\/doi.org\/10.1002\/1878-0261.13188","journal-title":"Mol Oncol"},{"key":"8087_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.breast.2022.07.010","volume":"65","author":"B Liu","year":"2022","unstructured":"Liu B, Hu Z, Ran J, Xie N, Tian C, Tang Y, Ouyang Q (2022) The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA. Breast 65:116\u2013123. https:\/\/doi.org\/10.1016\/j.breast.2022.07.010","journal-title":"Breast"},{"issue":"1","key":"8087_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall\u2019Olio FG, Madison RW, Fine AD, Oxnard GR, Graf RP, Stover DG (2023) Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol 34(1):111\u2013120. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.163","journal-title":"Ann Oncol"},{"issue":"23","key":"8087_CR28","doi-asserted-by":"publisher","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-22-2305","volume":"28","author":"J Tsuji","year":"2022","unstructured":"Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L, Rees R, Nardone A, Patterson C, Lennon NJ, Cibulskis C, Leshchiner I, Tayob N, Tolaney SM, Tung N, McDonnell DP, Krop IE, Winer EP, Stewart C, Jeselsohn R (2022) Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB\/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. Clin Cancer Res 28(23):5066\u20135078. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2305","journal-title":"Clin Cancer Res"},{"issue":"9","key":"8087_CR29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","volume":"29","author":"AA Davis","year":"2023","unstructured":"Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL\u2026 Ma CX (2023) Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4\/6 Inhibition in Hormone Receptor-Positive (HR+)\/HER2-Negative Metastatic Breast Cancer. Clin Cancer Res 29(9):1719\u20131729. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2177","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8087_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40364-023-00453-0","volume":"11","author":"X Guan","year":"2023","unstructured":"Guan X, Ma F, Li Q, Chen S, Lan B, Fan Y, Wang J, Luo Y, Cai R, Zhang P, Li Q, Xu B (2023) Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies. Biomark Res 11(1):21. https:\/\/doi.org\/10.1186\/s40364-023-00453-0","journal-title":"Biomark Res"},{"issue":"10","key":"8087_CR31","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/1878-0261.13416","volume":"17","author":"JW Chen","year":"2023","unstructured":"Chen JW, Jacot W, Cortes J, Krop IE, Dent S, Harbeck N, De Laurentiis M, Dieras V, Im YH, Stout TJ, Schimmoller F, Savage HM, Hutchinson KE, Wilson TR, ER+ (2023) HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Mol Oncol 17(10):2000\u20132016. https:\/\/doi.org\/10.1002\/1878-0261.13416","journal-title":"Mol Oncol"},{"issue":"9","key":"8087_CR32","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djad080","volume":"115","author":"MH Kim","year":"2023","unstructured":"Kim MH, Kim GM, Ahn JM, Ryu WJ, Kim SG, Kim JH, Kim TY, Han HJ, Kim JY, Park HS, Park S, Park BW, Kim SI, Jeong J, Lee J, Paik S, Kim S, Jung KH, Cho EH, Sohn J (2023) Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer. J Natl Cancer Inst 115(9):1036\u20131049. https:\/\/doi.org\/10.1093\/jnci\/djad080","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8087_CR33","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1038\/s41598-023-35925-8","volume":"13","author":"K Lee","year":"2023","unstructured":"Lee K, Lee J, Choi J, Sim SH, Kim JE, Kim MH, Park YH, Kim JH, Koh SJ, Park KH, Kang MJ, Ahn MS, Lee KE, Kim HJ, Ahn HK, Kim HJ, Park KU, Park IH (2023) Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2\u2009+\u2009metastatic breast cancer. Sci Rep 13(1):9928. https:\/\/doi.org\/10.1038\/s41598-023-35925-8","journal-title":"Sci Rep"},{"key":"8087_CR34","doi-asserted-by":"publisher","unstructured":"Pascual J, Gil-Gil M, Proszek P, Zielinski C, Reay A, Ruiz-Borrego M, Cutts R, Ciruelos Gil EM, Feber A, Munoz-Mateu M, Swift C, Bermejo B, Herranz J, Margeli Vila M, Anton A, Kahan Z, Csoszi T, Liu Y, Fernandez-Garcia D, \u2026 Martin M. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients. Clin Cancer Res. 2023;29(20):4166-77. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0956","DOI":"10.1158\/1078-0432.CCR-23-0956"},{"issue":"1","key":"8087_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12916-023-03017-z","volume":"21","author":"J Chiu","year":"2023","unstructured":"Chiu J, Su F, Joshi M, Masuda N, Ishikawa T, Aruga T, Zarate JP, Babbar N, Balbin OA, Yap YS (2023) Potential value of ctDNA monitoring in metastatic HR + \/HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. BMC Med 21(1):306. https:\/\/doi.org\/10.1186\/s12916-023-03017-z","journal-title":"BMC Med"},{"issue":"2","key":"8087_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-023-07144-2","volume":"203","author":"T Iwamoto","year":"2024","unstructured":"Iwamoto T, Niikura N, Watanabe K, Takeshita T, Kikawa Y, Kobayashi K, Iwakuma N, Okamura T, Tada H, Ozaki S, Okuno T, Toh U, Yamamoto Y, Tsuneizumi M, Ishiguro H, Masuda N, Saji S (2024) Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer. Breast Cancer Res Treat 203(2):225\u2013234. https:\/\/doi.org\/10.1007\/s10549-023-07144-2","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"8087_CR37","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1158\/1078-0432.Ccr-22-3573","volume":"30","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martin M (2024) Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer. Clin Cancer Res 30(10):2233\u20132244. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-3573","journal-title":"Clin Cancer Res"},{"issue":"2","key":"8087_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-23-0133","volume":"30","author":"DW Cescon","year":"2024","unstructured":"Cescon DW, Hilton J, Morales Murilo S, Layman RM, Pluard T, Yeo B, Park IH, Provencher L, Kim SB, Im YH, Wyce A, Krishnatry AS, Hicks K, Zhang Q, Barbash O, Khaled A, Horner T, Dhar A, Oliveira M, Sparano JA (2024) A Phase I\/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive\/HER2-negative Advanced or Metastatic Breast Cancer. Clin Cancer Res 30(2):334\u2013343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0133","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8087_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-023-07210-9","volume":"204","author":"J Zhong","year":"2024","unstructured":"Zhong J, Jiang H, Liu X, Liao H, Xie F, Shao B, Jia S, Li H (2024) Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer. Breast Cancer Res Treat 204(3):617\u2013629. https:\/\/doi.org\/10.1007\/s10549-023-07210-9","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"8087_CR40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","volume":"43","author":"A Vasseur","year":"2024","unstructured":"Vasseur A, Cabel L, Hego C, Takka W, Trabelsi Grati O, Renouf B, Lerebours F, Loirat D, Brain E, Cottu P, Sablin MP, Pierga JY, Callens C, Renault S, Bidard FC (2024) Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with circulating tumor DNA analysis. Oncogene 43(16):1214\u20131222. https:\/\/doi.org\/10.1038\/s41388-024-02986-6","journal-title":"Oncogene"},{"issue":"6","key":"8087_CR41","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdz085","volume":"30","author":"S Hrebien","year":"2019","unstructured":"Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, McEwen R, Ratnayake J, Maudsley R, Carr TH, de Bruin EC, Schiavon G, Oliveira M, Turner N (2019) Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol 30(6):945\u2013952. https:\/\/doi.org\/10.1093\/annonc\/mdz085","journal-title":"Ann Oncol"},{"issue":"1","key":"8087_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13058-021-01411-0","volume":"23","author":"L Darrigues","year":"2021","unstructured":"Darrigues L, Pierga JY, Bernard-Tessier A, Bieche I, Silveira AB, Michel M, Loirat D, Cottu P, Cabel L, Dubot C, Geiss R, Ricci F, Vincent-Salomon A, Proudhon C, Bidard FC (2021) Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast Cancer Res 23(1):31. https:\/\/doi.org\/10.1186\/s13058-021-01411-0","journal-title":"Breast Cancer Res"},{"key":"8087_CR43","doi-asserted-by":"publisher","unstructured":"Aguilar-Mahecha A, Lafleur J, Brousse S, Savichtcheva O, Holden KA, Faulkner N, McLennan G, Jensen TJ, Basik M, Early (2021) On-treatment levels and dynamic changes of genomic instability in circulating tumor DNA predict response to treatment and outcome in metastatic breast cancer patients. Cancers (Basel) 13(6). https:\/\/doi.org\/10.3390\/cancers13061331","DOI":"10.3390\/cancers13061331"},{"key":"8087_CR44","doi-asserted-by":"publisher","unstructured":"Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, \u2026 Pogue-Geile KL. NSABP FB-10: a phase Ib\/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer. Breast Cancer Res. 2024;26(1):69. https:\/\/doi.org\/10.1186\/s13058-024-01823-8","DOI":"10.1186\/s13058-024-01823-8"},{"issue":"10","key":"8087_CR45","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","volume":"2","author":"S Chandarlapaty","year":"2016","unstructured":"Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME (2016) Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2(10):1310\u20131315. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1279","journal-title":"JAMA Oncol"},{"issue":"1","key":"8087_CR46","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1038\/s41598-021-84999-9","volume":"11","author":"SH Sim","year":"2021","unstructured":"Sim SH, Yang HN, Jeon SY, Lee KS, Park IH (2021) Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer. Sci Rep 11(1):5566. https:\/\/doi.org\/10.1038\/s41598-021-84999-9","journal-title":"Sci Rep"},{"issue":"40","key":"8087_CR47","doi-asserted-by":"publisher","first-page":"66901","DOI":"10.18632\/oncotarget.11383","volume":"8","author":"R Gyanchandani","year":"2017","unstructured":"Gyanchandani R, Kota KJ, Jonnalagadda AR, Minteer T, Knapick BA, Oesterreich S, Brufsky AM, Lee AV, Puhalla SL (2017) Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget 8(40):66901\u201366911. https:\/\/doi.org\/10.18632\/oncotarget.11383","journal-title":"Oncotarget"},{"issue":"1","key":"8087_CR48","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1038\/s41598-021-86238-7","volume":"11","author":"A Muendlein","year":"2021","unstructured":"Muendlein A, Geiger K, Gaenger S, Dechow T, Nonnenbroich C, Leiherer A, Drexel H, Gaumann A, Jagla W, Winder T, Mayer F, Decker T (2021) Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. Sci Rep 11(1):6761. https:\/\/doi.org\/10.1038\/s41598-021-86238-7","journal-title":"Sci Rep"},{"issue":"5","key":"8087_CR49","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/cas.15304","volume":"113","author":"YM Chin","year":"2022","unstructured":"Chin YM, Shibayama T, Chan HT, Otaki M, Hara F, Kobayashi T, Kobayashi K, Hosonaga M, Fukada I, Inagaki L, Ono M, Ito Y, Takahashi S, Ohno S, Ueno T, Nakamura Y, Low SK (2022) Serial circulating tumor DNA monitoring of CDK4\/6 inhibitors response in metastatic breast cancer. Cancer Sci 113(5):1808\u20131820. https:\/\/doi.org\/10.1111\/cas.15304","journal-title":"Cancer Sci"},{"key":"8087_CR50","doi-asserted-by":"publisher","first-page":"e2300285","DOI":"10.1200\/PO.23.00285","volume":"8","author":"I Migliaccio","year":"2024","unstructured":"Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, Criscitiello C, Minisini AM, Moretti E, Risi E, Guarducci C, Nardone A, Biganzoli L, Benelli M, Malorni L (2024) Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive\/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial. JCO Precis Oncol 8:e2300285. https:\/\/doi.org\/10.1200\/PO.23.00285","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"8087_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, Garcia-Murillas I, Bliss JM, Turner NC (2018) Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun 9(1):896. https:\/\/doi.org\/10.1038\/s41467-018-03215-x","journal-title":"Nat Commun"},{"key":"8087_CR52","doi-asserted-by":"publisher","first-page":"11579","DOI":"10.1038\/ncomms11579","volume":"7","author":"JM Spoerke","year":"2016","unstructured":"Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT, Amler LC, Hampton GM, Johnston S, Krop I, Schmid P, Lackner MR (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579. https:\/\/doi.org\/10.1038\/ncomms11579","journal-title":"Nat Commun"},{"issue":"2","key":"8087_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","volume":"14","author":"B Kingston","year":"2024","unstructured":"Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H, Moretti L, Kilburn LS, Johnson H, Macpherson IR, Ring A, Bliss JM, Hou Y, Toy W, Katzenellenbogen JA, Chandarlapaty S, Turner NC (2024) ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer. Cancer Discov 14(2):274\u2013289. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1387","journal-title":"Cancer Discov"},{"issue":"9","key":"8087_CR54","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1158\/2159-8290.CD-21-1696","volume":"12","author":"P Savas","year":"2022","unstructured":"Savas P, Lo LL, Luen SJ, Blackley EF, Callahan J, Moodie K, van Geelen CT, Ko YA, Weng CF, Wein L, Silva MJ, Bujak AZ, Yeung MM, Ftouni S, Hicks RJ, Francis PA, Lee CK, Dawson SJ, Loi S (2022) Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discov 12(9):2058\u20132073. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1696","journal-title":"Cancer Discov"},{"key":"8087_CR55","doi-asserted-by":"publisher","unstructured":"Martinez-Rodriguez A, Fuentes-Antras J, Lorca V, Lopez de Sa A, Perez-Segura P, Moreno F, Garcia-Saenz JA, Garcia-Barberan V (2024) Molecular profiling of endocrine resistance in HR+\/HER2-metastatic breast cancer: insights from extracellular vesicles-derived DNA and ctDNA in liquid biopsies. Int J Mol Sci 25(23). https:\/\/doi.org\/10.3390\/ijms252313045","DOI":"10.3390\/ijms252313045"},{"key":"8087_CR56","doi-asserted-by":"publisher","unstructured":"Fuentes-Antras J, Martinez-Rodriguez A, Guevara-Hoyer K, Lopez-Cade I, Lorca V, Pascual A, de Luna A, Ramirez-Ruda C, Swindell J, Flores P, Lluch A, Cescon DW, Perez-Segura P, Ocana A, Jones F, Moreno F, Garcia-Barberan V, Garcia-Saenz JA (2023) Real-world use of highly sensitive liquid biopsy monitoring in metastatic breast cancer patients treated with endocrine agents after exposure to aromatase inhibitors. Int J Mol Sci 24(14). https:\/\/doi.org\/10.3390\/ijms241411419","DOI":"10.3390\/ijms241411419"},{"key":"8087_CR57","doi-asserted-by":"publisher","first-page":"e2200531","DOI":"10.1200\/PO.22.00531","volume":"7","author":"L Gerratana","year":"2023","unstructured":"Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D\u2019Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, Cristofanilli M (2023) Cyclin-Dependent Kinase 4\/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO Precis Oncol 7:e2200531. https:\/\/doi.org\/10.1200\/PO.22.00531","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"8087_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13058-024-01768-y","volume":"26","author":"J Park","year":"2024","unstructured":"Park J, Chang ES, Kim JY, Chelakkot C, Sung M, Song JY, Jung K, Lee JH, Choi JY, Kim NY, Lee H, Kang MR, Kwon MJ, Shin YK, Park YH, Choi YL (2024) c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive\/HER2-negative metastatic breast cancer. Breast Cancer Res 26(1):13. https:\/\/doi.org\/10.1186\/s13058-024-01768-y","journal-title":"Breast Cancer Res"},{"issue":"313","key":"8087_CR59","doi-asserted-by":"publisher","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7(313):313ra182. https:\/\/doi.org\/10.1126\/scitranslmed.aac7551","journal-title":"Sci Transl Med"},{"issue":"6","key":"8087_CR60","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/bjc.2017.25","volume":"116","author":"ME Moynahan","year":"2017","unstructured":"Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S (2017) Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2. Br J Cancer 116(6):726\u2013730. https:\/\/doi.org\/10.1038\/bjc.2017.25","journal-title":"Br J Cancer"},{"issue":"17","key":"8087_CR61","doi-asserted-by":"publisher","first-page":"e70101","DOI":"10.1002\/cam4.70101","volume":"13","author":"E Teran","year":"2024","unstructured":"Teran E, Lozano R, Rodriguez CA, Abad M, Figuero L, Munoz JA, Cigarral B, Rodrigues A, Sancho M, Gomez MA, Morchon D, Montero JC, Sayagues JM, Ludena MD, Fonseca E (2024) PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+\/HER2- breast cancer. Cancer Med 13(17):e70101. https:\/\/doi.org\/10.1002\/cam4.70101","journal-title":"Cancer Med"},{"issue":"3","key":"8087_CR62","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-023-06967-3","volume":"201","author":"TW Chen","year":"2023","unstructured":"Chen TW, Hsiao W, Dai MS, Lin CH, Chang DY, Chen IC, Wang MY, Chang SH, Huang SM, Cheng AL, Wu KW, Tan KT, Lu YS (2023) Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Breast Cancer Res Treat 201(3):377\u2013385. https:\/\/doi.org\/10.1007\/s10549-023-06967-3","journal-title":"Breast Cancer Res Treat"},{"key":"8087_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.breast.2020.04.004","volume":"52","author":"Z Yi","year":"2020","unstructured":"Yi Z, Liu B, Sun X, Rong G, Wang W, Li H, Guan X, Li L, Zhai J, Li C, Qian H, Ma F, Xu B (2020) Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. Breast 52:17\u201322. https:\/\/doi.org\/10.1016\/j.breast.2020.04.004","journal-title":"Breast"},{"issue":"1","key":"8087_CR64","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13073-023-01181-8","volume":"15","author":"KE Hutchinson","year":"2023","unstructured":"Hutchinson KE, Chen JW, Savage HM, Stout TJ, Schimmoller F, Cortes J, Dent S, Harbeck N, Jacot W, Krop I, Trabucco SE, Sivakumar S, Sokol ES, Wilson TR (2023) Multiple PIK3CA mutation clonality correlates with outcomes in taselisib\u2009+\u2009fulvestrant-treated ER+\/HER2-, PIK3CA-mutated breast cancers. Genome Med 15(1):28. https:\/\/doi.org\/10.1186\/s13073-023-01181-8","journal-title":"Genome Med"},{"issue":"4","key":"8087_CR65","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425\u2013439. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0","journal-title":"Lancet Oncol"},{"key":"8087_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41523-020-00201-9","volume":"6","author":"Z Yi","year":"2020","unstructured":"Yi Z, Rong G, Guan Y, Li J, Chang L, Li H, Liu B, Wang W, Guan X, Ouyang Q, Li L, Zhai J, Li C, Li L, Xia X, Yang L, Qian H, Yi X, Xu B, Ma F (2020) Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. NPJ Breast Cancer 6:59. https:\/\/doi.org\/10.1038\/s41523-020-00201-9","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"8087_CR67","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cac2.12032","volume":"40","author":"Z Yi","year":"2020","unstructured":"Yi Z, Ma F, Rong G, Guan Y, Li C, Xu B (2020) Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China. Cancer Commun (Lond) 40(6):260\u2013269. https:\/\/doi.org\/10.1002\/cac2.12032","journal-title":"Cancer Commun (Lond)"},{"issue":"14","key":"8087_CR68","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1002\/cam4.4652","volume":"11","author":"B Liu","year":"2022","unstructured":"Liu B, Yi Z, Guan Y, Ouyang Q, Li C, Guan X, Lv D, Li L, Zhai J, Qian H, Xu B, Ma F, Zeng Y (2022) Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Cancer Med 11(14):2767\u20132778. https:\/\/doi.org\/10.1002\/cam4.4652","journal-title":"Cancer Med"},{"issue":"3","key":"8087_CR69","doi-asserted-by":"publisher","first-page":"220","DOI":"10.21037\/atm-20-2137","volume":"9","author":"G Rong","year":"2021","unstructured":"Rong G, Yi Z, Ma F, Guan Y, Xu Y, Li L, Xu B (2021) DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis. Ann Transl Med 9(3):220. https:\/\/doi.org\/10.21037\/atm-20-2137","journal-title":"Ann Transl Med"},{"key":"8087_CR70","doi-asserted-by":"publisher","first-page":"550185","DOI":"10.3389\/fonc.2020.550185","volume":"10","author":"L Gerratana","year":"2020","unstructured":"Gerratana L, Basile D, Franzoni A, Allegri L, Viotto D, Corvaja C, Bortot L, Bertoli E, Buriolla S, Targato G, Da Ros L, Russo S, Bonotto M, Belletti B, Baldassarre G, Damante G, Puglisi F (2020) Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. Front Oncol 10:550185. https:\/\/doi.org\/10.3389\/fonc.2020.550185","journal-title":"Front Oncol"},{"issue":"1","key":"8087_CR71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1158\/2159-8290.CD-20-0553","volume":"11","author":"J Pascual","year":"2021","unstructured":"Pascual J, Lim JSJ, Macpherson IR, Armstrong AC, Ring A, Okines AFC, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, Hubank M, Hills M, King J, Parmar M, Prout T, Finneran L\u2026 Turner NC (2021) Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. Cancer Discov 11(1):92\u2013107. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0553","journal-title":"Cancer Discov"},{"key":"8087_CR72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.11.045","volume":"145","author":"H Li","year":"2021","unstructured":"Li H, Wang J, Yi Z, Li C, Wang H, Zhang J, Wang T, Nan P, Lin F, Xu D, Qian H, Ma F (2021) CDK12 inhibition enhances sensitivity of HER2\u2009+\u2009breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K\/AKT. Eur J Cancer 145:92\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.045","journal-title":"Eur J Cancer"},{"issue":"2","key":"8087_CR73","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1373\/clinchem.2016.261834","volume":"63","author":"K Page","year":"2017","unstructured":"Page K, Guttery DS, Fernandez-Garcia D, Hills A, Hastings RK, Luo J, Goddard K, Shahin V, Woodley-Barker L, Rosales BM, Coombes RC, Stebbing J, Shaw JA (2017) Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. Clin Chem 63(2):532\u2013541. https:\/\/doi.org\/10.1373\/clinchem.2016.261834","journal-title":"Clin Chem"},{"issue":"5","key":"8087_CR74","doi-asserted-by":"publisher","first-page":"EVIDoa2300231","DOI":"10.1056\/EVIDoa2300231","volume":"3","author":"MR Lloyd","year":"2024","unstructured":"Lloyd MR, Brett JO, Carmeli A, Weipert CM, Zhang N, Yu J, Bucheit L, Medford AJ, Wagle N, Bardia A, Wander SA (2024) CDK4\/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer. NEJM Evid 3(5):EVIDoa2300231. https:\/\/doi.org\/10.1056\/EVIDoa2300231","journal-title":"NEJM Evid"},{"issue":"1","key":"8087_CR75","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M\u2026 Arteaga CL (2019) Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat Commun 10(1):1373. https:\/\/doi.org\/10.1038\/s41467-019-09068-2","journal-title":"Nat Commun"},{"key":"8087_CR76","doi-asserted-by":"publisher","unstructured":"Raimondi L, Raimondi FM, Pietranera M, Di Rocco A, Di Benedetto L, Miele E, Lazzeroni R, Cimino G, Spinelli GP (2021) Assessment of resistance mechanisms and clinical implications in patients with KRAS mutated-metastatic breast cancer and resistance to CDK4\/6 inhibitors. Cancers (Basel) 13(8). https:\/\/doi.org\/10.3390\/cancers13081928","DOI":"10.3390\/cancers13081928"},{"issue":"1","key":"8087_CR77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/annonc\/mdx483","volume":"29","author":"C Fribbens","year":"2018","unstructured":"Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O\u2019Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner N (2018) Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol 29(1):145\u2013153. https:\/\/doi.org\/10.1093\/annonc\/mdx483","journal-title":"Ann Oncol"},{"issue":"3","key":"8087_CR78","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","volume":"26","author":"A Pearson","year":"2020","unstructured":"Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, O\u2019Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, Lopez-Knowles E, Schuster EF, Dowsett M\u2026 Turner NC (2020) Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clin Cancer Res 26(3):608\u2013622. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4044","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8087_CR79","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/s41467-021-22605-2","volume":"12","author":"B Kingston","year":"2021","unstructured":"Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, Swift C, Kilburn LS, Kernaghan S, Moretti L, Wilkinson K, Wardley AM, Macpherson IR, Baird RD, Roylance R, Reis-Filho JS, Hubank M, Faull I, Banks KC\u2026 Turner NC (2021) Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun 12(1):2423. https:\/\/doi.org\/10.1038\/s41467-021-22605-2","journal-title":"Nat Commun"},{"issue":"9","key":"8087_CR80","doi-asserted-by":"publisher","first-page":"e2431722","DOI":"10.1001\/jamanetworkopen.2024.31722","volume":"7","author":"K Dickinson","year":"2024","unstructured":"Dickinson K, Sharma A, Agnihotram RV, Altuntur S, Park M, Meterissian S, Burnier JV (2024) Circulating Tumor DNA and Survival in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open 7(9):e2431722. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.31722","journal-title":"JAMA Netw Open"},{"key":"8087_CR81","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744. https:\/\/doi.org\/10.1038\/ncomms7744","journal-title":"Nat Commun"},{"issue":"3","key":"8087_CR82","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.20.01572","volume":"39","author":"DF Hayes","year":"2021","unstructured":"Hayes DF (2021) Defining Clinical Utility of Tumor Biomarker Tests: A Clinician\u2019s Viewpoint. J Clin Oncol 39(3):238\u2013248. https:\/\/doi.org\/10.1200\/JCO.20.01572","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08087-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08087-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:11:23Z","timestamp":1790604683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08087-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8087"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08087-0","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HBL reports receiving travel, accommodation, and conference fee support from AstraZeneca for attendance at the ESMO Breast Cancer Congress in Munich 2025. AstraZeneca had no role in the conception, design, analysis, or writing of this manuscript. KLS reports receiving grants from the Novo Nordisk Foundation, Danish Cancer Society (grant number R343-A19765), Danish Comprehensive Cancer Center (grant number DCCC16-2022 ctDNA-RECIST), Kr\u00e6ftfonden, and Health Research Foundation Central Denmark Region (grant number A3656) during the conduct of the review. Lectures sponsored by Incyte Biosciences Distribution, Bristol-Myers Squibb Denmark, Servier Danmark A\/S, and Daiichi Sankyo Nordics ApS The remaining authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23"}}